



- *Department of Medicine*
 - *Western Hematology-Oncology*
 - *Division of Oncology*
-

Conditions Treated:

- *Lung Nodules*
- *Mesothelioma*
- *Pleural Effusion*
- *Lung Metastases*
- *Hematologic Diseases*
- *All forms of Cancer*

Research Areas:

- *Medical Oncology*

Programs & Services:

- *Department of Medicine*
- *Cancer Care*
- *Division of Oncology*

I am a clinical hematology/oncology physician. I see all types of hematologic disorders and every type of cancer. I am interested in cooperative group oncology clinical trials to promote best practice in oncology to achieve optimal results.

Board Certification

2003: Medical Oncology
2003: Hematology
2000: Internal Medicine

Education

1997 University of Miami School of Medicine, Miami, FL,

Residency

2000 Tripler Army Medical Center, Tripler, HI, Internal Medicine

Fellowship

2003 Brooke Army Medical Center, Ft. Sam Houston, TX, Hematology/Oncology

Teaching or Professional Positions

2013-2015: Levine Cancer Institute, Leukemia Committee
2013-2015: Levine Cancer Institute, Upper/Lower GI Cancer Committee
2013-2015: Levine Cancer Institute, Genetic Committee
2007-2008: Chief, Hematology/Oncology Services, Brooke Army Medical Center
2006-2008: Assistant Program Director, SAUSWEC Hematology/Oncology Fellowship
2004-2005: Chief Medical Services, 115th Field Hospital

Professional Memberships

ASCO
American Society Hematology

Awards & Recognition

2005-2006: UTHSCA Outstanding Faculty Award for 3rd year Medical Student
2005: Bronze Star, Operation Iraqi Freedom II
2000: William J Uphouse Award for most compassionate physician

Publications

Schwartz Garry H and Jones Christopher B. et al. A Phase I and Pharmacokinetic Study of Non-polyglutamatable Thymidylate Synthase Inhibitor ZD9331 and Docetaxel in Patients with Advanced Solid Malignancies. Investigational New Drugs 22: 437-448, 2004.

Mita AC, Hammond LA, Jones CB et al. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12: 5207-5215, 2006.

R.F. Setlik, G. Preston, C.B Jones et al. A Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer. ASCO Clinical Proceedings, Abstract #2045, 2006

Shumway NM, Jones CB, and Terrazzino S. Randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. ASCO Clinical Proceedings, Abstract 9633, 2009

Doctor's Contact Information

Office: 303.650.4042 or 303.232.0602
Alternate: 877.225.5654
Fax: 303.650.4046 or 303.988.8750

Locations

Western Hematology Oncology
400 Indiana Street
Red Rocks Medical Center #230
Golden, CO 80401